30 March 2021
Rymarz Zdort advised ExploRNA Therapeutics in the process of an equity investment that involved a subscription for shares in ExploRNA Therapeutics by the fund Black Forest SICAV-SIF (owned by Michał Sołowow) and the provision of funds for the expansion of the former’s operations.
ExploRNA Therapeutics is a biotech spin-off company of the University of Warsaw, which develops ground-breaking mRNA modification technologies paving the way for new therapeutic applications of mRNA in medicine, such as COVID-19 vaccines.
Black Forest SICAV-SIF is an investment fund supporting scientific and technological advancements achieved by both Polish and foreign companies. Active in a number of industries and sectors, Black Forest’s net asset value has now exceeded EUR 4.1 billion. Products manufactured by its companies are sold throughout the world (in more than 60 countries, in six continents).
The investment by Black Forest SICAV-SIF will allow ExploRNA Therapeutics to develop and implement an ambitious research program focusing on the use of mRNA for therapeutic purposes and enhancing the company’s research potential.
8 December 2023
We are pleased to announce that thanks to our hard work and the projects on which we advised this past year, our Fintech practice has again been recognised in the 2024 edition of the Chambers FinTech ...
4 December 2023
We are pleased to announce that Rymarz Zdort Maruta advised Citylink (CL Property), a nationwide developer specialising in modern, multi-functional facilities, on the entire negotiation process regard...
29 November 2023
We are pleased to announce that we advised a fund of MCI Capital on a transaction involving the acquisition of a majority stake in Webcon sp. z o.o. (“Webcon”), a leading Polish low-code software deve...
